UNION therapeutics to present at the Dermatology Summit 2023
· UNION invited to present orismilast at the Dermatology Summit 2023 · Orismilast is a potent next-generation PDE4 inhibitor with broad anti-inflammatory properties in development as a first-in-class or best-in-class treatment for psoriasis, atopic dermatitis (AD) and hidradenitis suppurativa (HS) · Access to recorded presentation available after the conference at UNION’s website Hellerup, Denmark, 7 December 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases,